Accretion Pha.
: ACCPL · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Accretion Pha.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Accretion Pharmaceuticals Limited is a pharmaceutical company established in 2012 that specialises in the manufacture and sale of tablets, capsules, and various healthcare products. The company operates across both generic and branded segments, providing contract and third-party manufacturing services to domestic and international clients.
Business Model
The company generates revenue through the production and supply of pharmaceutical formulations to private institutions, government bodies, and other pharmaceutical firms. It leverages its manufacturing capabilities to provide third-party and contract manufacturing services.
Growth Outlook
Growth is expected to be driven by the expansion of its contract manufacturing services and the continued supply of pharmaceutical products to both domestic and international markets.
Key Risks
- Regulatory Compliance. The company faces risks associated with stringent quality standards and inspections by domestic and international health authorities.
- Pricing Pressure. Intense competition in the generic pharmaceutical market may lead to margin compression and pricing volatility.
- Supply Chain Dependency. Disruptions in the procurement of active pharmaceutical ingredients (APIs) could adversely impact manufacturing timelines and profitability.
- Government Policy Changes. Changes in government procurement policies or drug pricing regulations could significantly affect revenue streams from the public sector.
Start your research today
Unlock AI insights, financials, peers and live data on Accretion Pha. and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Accretion Pha.ACCPL | ₹222 Cr | — | — | — | 16.7% | — | — | +229.8% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Accretion Pha.
: ACCPL · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Accretion Pha.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Accretion Pharmaceuticals Limited is a pharmaceutical company established in 2012 that specialises in the manufacture and sale of tablets, capsules, and various healthcare products. The company operates across both generic and branded segments, providing contract and third-party manufacturing services to domestic and international clients.
Business Model
The company generates revenue through the production and supply of pharmaceutical formulations to private institutions, government bodies, and other pharmaceutical firms. It leverages its manufacturing capabilities to provide third-party and contract manufacturing services.
Growth Outlook
Growth is expected to be driven by the expansion of its contract manufacturing services and the continued supply of pharmaceutical products to both domestic and international markets.
Key Risks
- Regulatory Compliance. The company faces risks associated with stringent quality standards and inspections by domestic and international health authorities.
- Pricing Pressure. Intense competition in the generic pharmaceutical market may lead to margin compression and pricing volatility.
- Supply Chain Dependency. Disruptions in the procurement of active pharmaceutical ingredients (APIs) could adversely impact manufacturing timelines and profitability.
- Government Policy Changes. Changes in government procurement policies or drug pricing regulations could significantly affect revenue streams from the public sector.
Start your research today
Unlock AI insights, financials, peers and live data on Accretion Pha. and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026